FACULTY
Aparna Parikh, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Attending Oncologist
Hematology and Oncology
Massachusetts General Hospital
Boston, MA
Ryan Corcoran, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Associate Professor, Cancer Center
Massachusetts General Hospital
Boston, MA
PROGRAM OVERVIEW
This live virtual symposium is focused on the team involved in the care of the people who undergo screening for cancer.
TARGET AUDIENCE
This activity is intended for primary care physicians, internists, family practice physicians, and related healthcare professionals involved in the care of people who undergo screening for cancer.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Evaluate the science behind cfDNA testing along with its role in early multi-cancer detection
- Describe the potential benefits and limitations of using routine cfDNA screening to identify a variety of cancer types
- Plan strategies to integrate cfDNA blood tests and early multicancer detection into daily practice
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live virtual symposium for a maximum of 1.25 AMA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of people who undergo screening for cancer.
Credits: 1.25 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/(CCM) is accredited as a provider of nursing continuing professional education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.25 contact hour of continuing nursing education of RNs and APNs.
AAFP CREDIT REQUEST
The AAFP has reviewed Earlier Cancer Detection: The Growing Role of Cell-Free DNA (cfDNA) Blood Tests in Primary Care and deemed it acceptable for up to 1.25 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 10/01/2021 to 10/01/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Aparna Parikh, MD reports the following relationships:
Relationship | Manufacturer |
Consultant/Advisory Board | Pfizer, Eli Lilly, Natera, and Checkmate |
Research funding (Institution) | Bristol Myers Squibb, Guardant, Array, Pfizer, Macrogenics, Puretech, PMV Pharma, Plexxikon, and Takeda |
Data Safety Monitor Committee | Roche |
Stock Ownership | C2i |
Ryan Corcoran, MD, PhD reports the following relationships:
Relationship | Manufacturer |
Consultant/Advisory Board | AbbVie, Amgen, Array Biopharma/Pfizer, Asana Biosciences, Astex Pharmaceuticals, AstraZeneca, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Elicio, Erasca, Fog Pharma, Genentech, Guardant Health, Ipsen, Kinnate Biopharma, LOXO, Merrimack, Mirati Therapeutics, Naterna, Navire, N-of-one/Qiagen, Novartis, nRichx, Remix Therapeutics, Revolution Medicines, Roche, Roivant, Shionogi, Shire, Spectrum Pharmaceuticals, Symphogen, Tango Therapeutics, Taiho, Warp Drive Bio, and Zikani Therapeutics. |
Equity | Avidity Biosciences, C4 Therapeutics, Erasca, Kinnate Biopharma, nRichDx, Remix Therapeutics, and Revolution Medicines |
Research Funding | Asana, AstraZeneca, Lilly, and Novartis |
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Chris Drury, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the live virtual activity; and
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
DISCLAIMER
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.